Adding Lenvatinib to Pembrolizumab Does Not Provide Additional Benefit in Patients with Unresectable Advanced Melanoma By Ogkologos - September 10, 2025 400 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LEAP-003 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR Courageous children receive Star Awards in virtual celebration December 17, 2021 March is Multiple Myeloma Action Month March 29, 2022 Hospital Mistakenly Gave Woman a Mastectomy, Then Postponed Her Reconstruction for... July 12, 2021 Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia June 17, 2019 Load more HOT NEWS Tough questions for tough times in clinical research Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk... Workout Wednesdays – Chest Exercises Part 1 Can mRNA Vaccines Help Treat Cancer?
